Clinical trials: SARS-CoV-2 Seroprevalence
SARS-CoV-2 Seroprevalence
ANC COVID-19 Surveillance
The purpose of this observational study is to determine the seroprevalence of SARS-CoV-2 antibodies in the community with pregnant women aged 15-49 years attending first antenatal care as the sentinel population.
- Trial name
- NCT07021807
- Where
- Zambia
- Volunteers
- 9,111 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Covid19, Surgery
Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery
We have herein analysed the patients admitted to our Department that underwent serologic tests for SARS-CoV-2 either by Ab or RT PCR, to estimate the prevalence of COVID-19 in the setting of a non-dedicated COVID-19 hospital and…
- Conditions
- Covid19, Surgery, SARS (Severe Acute Respiratory Syndrome)
- Trial name
- NCT04480580
- Testing
- SARS-CoV-2 Ab
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Cagliari
SARS-CoV Infection, Covid19
The CHILD Cohort COVID-19 Add-On Study
The objective of this study is to determine the prevalence and transmission of SARS-CoV-2 infection among Canadian children and parents in the CHILD cohort, identify predictors of infection susceptibility and severity, and…
- Trial name
- NCT05234359
- Testing
- Serology Testing, Stool sample
- Where
- Canada
- Volunteers
- 5,385 people
- Sponsor
- University of Manitoba
Coronavirus Infection, Prevalence
Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19)
In order to inform the public decision on the containment strategy and knowledge of the intensity of the epidemic during post-containment, estimates of the share of the population infected with the SARS-CoV-2 virus responsible…
- Trial name
- COVAL-NANCY (NCT04448769)
- Testing
- Anti-SARS-CoV-2 IgT seropositivity
- Where
- France
- Volunteers
- 2,006 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Covid19, SARS-CoV-2 Infection
SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19)
Assessment of the seroprevalence and sero-incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) among Nursing Home (NH) residents and staff in Belgium.
- Trial name
- SCOPE (NCT04738695)
- Testing
- Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)
- Where
- Belgium
- Volunteers
- 3,008 people, healthy volunteers welcome
- Sponsor
- Sciensano
Sars-CoV2
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak
A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- COVEMUZ (NCT04426292)
- Testing
- Serological testing
- Where
- Belgium
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
SARS-CoV Infection
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination
A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04880174
- Testing
- serological testing
- Where
- Belgium
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
SARS-CoV 2, COVID-19
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
The purpose of this study is to identify healthcare workers with SARS CoV 2 antibodies who have not been previously diagnosed and are presumed COVID-19 negative, then determine the level of immunity in this population which could…
- Trial name
- NCT04383587
- Testing
- Serologic testing
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Healthy Volunteers
Defining the COVID-19 Immunity Denominator in the Mekong: a Cross-Sectional Seroprevalence Study of SARS-CoV-2 in HealthyVolunteers
Background: In early 2020, many people thought Cambodia would have a serious COVID-19 outbreak due to the high number of Chinese travelers going to Cambodia.
- Trial name
- NCT04594395
- Where
- 2 sites in Cambodia
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2 Serological Status, SARS-CoV-2 Seroprevalence
Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)
COVID-19 is a new emerging disease caused by infection with the SARS-CoV-2 coronavirus, with no specific therapeutic options. Since the end of February 2020, the Strasbourg University Hospital (HUS) had faced a sudden increase of…
- Trial name
- SeroCoV-HUS (NCT04441684)
- Testing
- Blood sample for serological test
- Where
- France
- Volunteers
- 1,466 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
SARS-CoV2
Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP
The purpose of this study is to define seroprevalence of anti-SARS-CoV2 among children of Hospital Workers in APHP, particularly exposed population, according to parents' SARS-CoV2 serological status.
- Trial name
- FamilyPEDCOVID (NCT04442087)
- Testing
- Serology SARS-CoV2, Data collection
- Where
- France
- Volunteers
- 563 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SARS-CoV-2
Seroprevalence of Coronavirus Disease 2019 (COVID-19) Antibodies in a Vulnerable Neighbourhood, Buenos Aries Argentina
Background The study aimed to establish the seroprevalence of SARS-COV-2 in an Argentinian slum three months after the first case was reported.
- Trial name
- NCT04472078
- Testing
- Serological Assay or IgG for SARS-CoV-2
- Where
- Argentina
- Volunteers
- 873 people
- Sponsor
- Hospital Italiano de Buenos Aires
HIV Infections
COVID-19 Prevalence in HIV-infected Patients
North-east area of France was hit in February 2020 by the new coronavirus disease, more severely than other French regions. Factors affecting the evolution of the disease and its severity have been quickly identified, among them…
- Trial name
- SeCoVIHA (NCT04515225)
- Testing
- Blood Sample
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Strasbourg, France
COVID-19 Pandemic, Transplantation, Kidney
Seroprevalence of the Anti-SARS-CoV-2 Antibodies (Causing COVID-19) in Kidney Transplant Recipients in Severely Affected Region
Goal of this study is to evaluate the seroprevalence of anti-SARS-CoV-2 antibodies in patients after kidney transplantation who are one of the risk groups for the severe course of the infection and map the progression of the…
- Trial name
- SECOVtx (NCT04874740)
- Testing
- No intervention
- Where
- Czechia
- Volunteers
- 300 people
- Sponsor
- University Hospital Ostrava
Covid19
Prevalence of COVID-19 Antibodies Kingman AZ
The COVID-19 disease outbreak is a historic event that has challenged medical systems in the United States. Currently, most reports of confirmed cases rely on the testing of symptomatic patients.
- Trial name
- NCT04533360
- Testing
- VITROS Anti-SARS-CoV-2 IgG test
- Where
- United States
- Volunteers
- 566 people, healthy volunteers welcome
- Sponsor
- Kingman Regional Medical Center